Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 3
Submit an article Journal homepage
175
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman’s disease

Kazutoshi Ebisawaa Department of Haematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Arika Shimuraa Department of Haematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Akira Hondaa Department of Haematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Yosuke Masamotoa Department of Haematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Fumio Nakaharaa Department of Haematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
&
Mineo Kurokawaa Department of Haematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;b Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, JapanCorrespondence[email protected]
Pages 614-619 | Received 11 Jul 2020, Accepted 03 Oct 2020, Published online: 19 Oct 2020

References

  • Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206–216.
  • Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–1657.
  • Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353–1364.
  • van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–2124.
  • Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(10):1839–1849.
  • Tabata S, Higuchi T, Tatsukawa S, et al. Idiopathic multicentric Castleman disease with autoimmune hemolytic anemia and production of anti-drug antibody against tocilizumab. Intern Med. 2019;58(22):3313–3318.
  • Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163–175–e175.
  • Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
  • Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25(22):3350–3356.
  • Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol. 2011;29(18):2481–2486.
  • Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677–684.
  • Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–2632.
  • van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–974.
  • Bijlsma JWJ, Buttgereit F. Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies. Rheumatology (Oxford). 2016;55(suppl 2):ii3–ii5.
  • Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–123.
  • Morra DE, Pierson SK, Shilling D, et al. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol. 2019;184(2):232–241.
  • Kawabata H, Kadowaki N, Nishikori M, et al. Clinical features and treatment of multicentric castleman's disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop. 2013;53(1):69–77.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.